Protagonist Therapeutics Secures FDA Approval for MIMRYLO to Treat Polycythemia Vera

AI-generated NewsSnap summary based on source reporting.
Published: 2026-08-29
Category: business
Source: AP News
Original source

Protagonist Therapeutics has received U.S. FDA approval for its hepcidin mimetic peptide, MIMRYLO (rusfertide), for the treatment of Polycythemia Vera. This approval introduces a new therapeutic option for patients with this chronic blood disorder, potentially improving disease management and patient outcomes.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai